Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Wente, MN; Sauer, P; Mehrabi, A; Weitz, J; Büchler, MW; Schmidt, J; Schemmer, P.
Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation.
Clin Transplant. 2006; 20 Suppl 17(2):80-84
Doi: 10.1111/j.1399-0012.2006.00605.x
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Schemmer Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Non-compliance in solid transplantation recipients is a major factor in acute graft rejection, which influences patient survival. Nowadays, tacrolimus is one of the most widely used immunosuppressant agents together with cyclosporine following kidney and liver transplantation with a standardized twice-daily dosing regimen. To improve the patients' compliance to the prescribed immunosuppressive therapy, FK506E (MR4), a modified release (MR) oral dosage form of tacrolimus has been developed for a once-daily dosing regimen. This report reviews the most recent results of clinical trials with MR tacrolimus after kidney and liver transplantation.
- Find related publications in this database (using NLM MeSH Indexing)
- Delayed-Action Preparations -
- Humans -
- Immunosuppressive Agents - administration & dosage
- Kidney Transplantation -
- Liver Transplantation -
- Tacrolimus - administration & dosage
- Find related publications in this database (Keywords)
- compliance
- immunosuppression
- kidney transplantation
- liver transplantation
- tacrolimus